Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease

Trépo, Eric; Potthoff, Andrej; Pradat, Pierre; Bakshi, Rakesh K.; Young, Bradford A.; Lagier, Robert; Moreno, Christophe; Verset, Laurine; Cross, R; Degré, Delphine; Lemmers, Arnaud; Gustot, Thierry; Berthillon, Pascale; Rosenberg, William; Trépo, C.; Sninsky, John J.; Adler, Michaël; Wedemeyer, Heiner

doi:10.1016/j.jhep.2010.10.018

Cited by 53 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Direct markers reflect the extracellular matrix metabolism. Among these, the enhanced liver fibrosis score, a combination of matrix components and functional inhibitors of their degradation, has been validated as a non-invasive marker of liver fibrosis in cross-sectional studies of different liver disease aetiologies [5,26,27]. However, direct markers are generally expensive and available only in reference or research laboratories.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, Huang et al, by analysing DNA extracted from whole blood, identified a seven-gene variant signature associated with fibrosis progression, the cirrhosis risk score [28]. Although this test has been validated in longitudinal, retrospective studies, the costs, the availability, and the inability to differentiate degrees of fibrosis, particularly in females, still limit its widespread use [27,29].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C

Rocco

Nucci

Valente

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C

Rocco

Nucci

Valente

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

“…Recent advances and declining costs of high-throughput genotyping technology have led to an increasing number of genome-wide association studies to assess disease progression. In addition to the previously validated cirrhosis risk score [35], polymorphisms in the various genes encoding MMP-1 and 9, MCP1, PNPLA3, and vitamin D receptor have also been associated with fibrosis progression in CHC [8].…”

Section: Genomic and Proteomic Markers Of Fibrosismentioning

confidence: 98%

Current status of fibrosis markers

Patel

Shackel

2014

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Current noninvasive tests of fibrosis provide good diagnostic and prognostic utility for advanced stage liver disease, and have been adapted into clinical practice for CHC. Reliable biomarkers for steatosis, nonalcoholic steatohepatitis, and assessment of fibrosis progression in chronic liver disease are still required. Continued advances in bioimaging and functional genomics will be important for quantitative assessment of fibrosis and future biomarker development.

show abstract

“…CRS remained the only variable associated with fibrosis progression in multivariate analysis, including gender and alcohol intake [28].…”

Section: Il10mentioning

confidence: 95%

Genomics and HCV infection: Progression of fibrosis and treatment response

Estrabaud

Vidaud

Marcellin

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

HCV infection is a global health problem that affects 170 million people worldwide. The severity of the disease varies from asymptomatic chronic infection to cirrhosis and hepatocellular carcinoma (HCC). Recently, the standard of care for genotype 1 patients has greatly improved with the addition of protease inhibitors (telaprevir or boceprevir) to pegylated interferon (PegIFN) and ribavirin (RBV). The prediction of fibrosis progression and the response to antiviral treatment are two major issues in the management of patients with chronic hepatitis C. Differential expression of mRNAs was first analyzed for both progression of fibrosis and treatment response. Specific polymorphisms, associated with either fibrosis or viral response, were identified thanks to major improvements in genome scanning technologies. Since 2009, several independent genome wide association studies (GWAS) have reported an association between genetic polymorphisms within the IL-28B promoter and both natural and treatment-induced clearance in genotype 1 infected patients. These different studies showed the strong association and the importance of IL-28B polymorphisms in the treatment response. Combining the different genetic factors could improve their predictive value and help identify patients at a high risk of progression of fibrosis as well as those with a lower chance of responding to treatment. The aim of this review was to discuss the genomic factors (mRNAs, miRNAs, and SNPs) and HCV infection with clinical implications for either progression of fibrosis or treatment response. Recent findings on the IL-28B polymorphism and its application in clinical practice will also be discussed.

show abstract

Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease

Cited by 53 publications

References 33 publications

13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C

13C-Aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C

Current status of fibrosis markers

Genomics and HCV infection: Progression of fibrosis and treatment response

Contact Info

Product

Resources

About